Biocomposites, a global medical devices company specialising in infection management for bone and soft tissue, has received expanded approval from India’s Central Drugs Standard Control Organisation (CDSCO) for its flagship product, STIMULAN Rapid Cure.

The new approval permits the product to be mixed with a broader range of antibiotics—both individually and in combination—as well as with antifungals to support wound healing and infection treatment.

STIMULAN Rapid Cure is already the only calcium matrix approved to be mixed with an antibiotic for use in bone and surrounding soft tissue, having received that authorisation in more than 60 countries worldwide. With this latest development, India becomes the first country globally to approve STIMULAN Rapid Cure to be mixed with antifungals, expanding the options available to surgeons when deciding on treatment strategies for their patients.

Surgical site infections and antimicrobial resistance remain major global health challenges contributing to increased mortality worldwide. The expanded approval for STIMULAN Rapid Cure gives surgeons greater flexibility to address these challenges, enabling them to tailor antimicrobial selection to the specific clinical needs of each patient.

Michael Harris, Chief Executive Officer of Biocomposites, said, “This expanded approval for STIMULAN Rapid Cure will allow surgeons in India to tailor antimicrobial treatment strategies to their patients’ needs. STIMULAN Rapid Cure already helps more than 150,000 patients worldwide every year, and is an important tool for surgeons as they tackle the impact of antimicrobial resistance and help their patients.”

Headquartered in Keele, UK, Biocomposites operates across Europe, South America, the USA, Canada, China and India, and is recognised as a global leader in innovative calcium compounds and bone cements for surgical use.